Peer-reviewed Artikel
Int J Cancer. 2004; 108: 162-166
Alterations of DeltaTA-p 73 splice transcripts during melanoma development and progression.
Tuve S, Wagner S, Schittek B, Pützer BM.Clin Cancer Res. 2004; 10:626-633.
Quantitative TP73 transcript analysis in hepatocellular carcinomas.
Stiewe T, Tuve S, Peter M, Tannapfel A, Elmaagacli AH, Pützer BM.J Hepatol. 2004; 40:354-356.
Diagnosis of biliary duct cysts in transgenic mice expressing the hepatitis B virus X-protein.
Dirsch O, Rödicker F, Herborn CU, Hilken G, Pützer BM.Cell Death Differ. 2003; 10:612-614.
Increased DN-p73 expression in tumors by upregulation of the E2F1-regulated, TA-promotor derived DN'-p73 transcript.
Pützer BM, Tuve S, Tannapfel A, Stiewe T.J Biol Chem. 2003; 278:14230-14236.
Inactivation of the RB tumor suppressor gene by oncogenic isoforms of the p53 family member p73.
Stiewe T, Stanelle J, Theseling CC, Pollmeier B, Beitzinger M, Pützer BM.Cancer Res. 2003; 63:2737-2741.
p73 is effective in p53-null pancreatic cancer cells resistant to wild-type TP53 gene replacement.
Rödicker F, Pützer BM.J Mol Med 2003; 81:411-419.
Gene therapeutic approaches for medullary thyroid carcinoma treatment.
Drosten M, Pützer BM.Hum Gene Ther. 2003; 14:971-982.
Antitumor capacity of dominant-negative RET proto oncogene mutant in a medullary thyroid carcinoma model.
Drosten M, Stiewe T, Pützer BM.Cardiovasc Res. 2003; 59:512-519.
Mechanism of E2F1-induced apoptosis in primary vascular smooth muscle cells.
Stanelle J, Stiewe T, Rödicker F, Köhler K, Theseling CC, Pützer BM.Mol Ther. 2002; 5:405-412.